High Court Offers Opinion, But Merck-Integra Fight Remanded
The perpetual tussle between lower drug costs for consumers and higher profits for the shareholders of biotechnology and pharmaceutical firms drew more limelight - if such a thing is possible - with last week's ruling by the U.S. Supreme Court that patent holders cannot stop other firms from starting related research.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter